Prosecution Insights
Last updated: July 17, 2026
Application No. 18/569,157

NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR

Final Rejection §DP
Filed
Dec 11, 2023
Priority
Jun 24, 2021 — RE 10-2021-0082699 +1 more
Examiner
SHIAO, REI TSANG
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
LG Chem Ltd.
OA Round
2 (Final)
80%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
46%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
1639 granted / 2053 resolved
+19.8% vs TC avg
Minimal -34% lift
Without
With
+-34.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
52 currently pending
Career history
2081
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
33.2%
-6.8% vs TC avg
§102
3.8%
-36.2% vs TC avg
§112
9.4%
-30.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 2053 resolved cases

Office Action

§DP
18569157Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Priority and Status of Claims 1. This application is a 371 of PCT/KR2022/009038 06/24/2022, which claims benefit of the foreign application KOREA, REPUBLIC OF KR10-2021-0082699 06/24/2021. 2. amendment of claims 11 and 14, cancelation of claim 10, and addition of claims 15-16 in the amendment filed on 5/11/2026 is acknowledged. Claims 1-9 and 11-16 are pending in the application. No matter has been found. Since the newly added claims 15-16 are commensurate within the scope of invention, claims 1-9 and 11-16 are prosecuted in the case. Responses to Amendments/Arguments 3. The rejection of claim 11 under 35 U.S.C. 112 (a) has been overcome in the amendment filed on 5/11/2026. Since claim 10 has been canceled, therefore the rejection of claim 10 under 35 U.S.C. 112 (a) has been obviated herein. 4. Since Xi et al. ‘239 does not disclose the instant compounds of formula (1), therefore it is distinct from the instant invention. The rejection of claim 1 under 35 U.S.C. 102 (a)(1) has been withdrawn herein. 5. Since Xi et al. ‘239 does not disclose the instant compounds of formula (1), therefore it is distinct from the instant invention. The rejection of claims 1-9 and 11-14 under 35 U.S.C. 103 (a) has been withdrawn herein. Since claim 10 has been canceled, therefore the rejection of claim 10 under 35 U.S.C. 103 (a) has been obviated herein. 6. Since a terminal disclaimer against Ham et al. ‘515 has not been filed to the Office, therefore the provisional rejection of claim 1 under obviousness-type double patenting over Ham et al. ‘515 is maintained. Applicants are requested to file a terminal disclaimer to the Office to overcome the rejection. Claim Objections 7. Claim 7, line 18 on page 6, is objected to as having a typographic error. Elimination of the space between the term “acrylic” and “acrylamido” would obviate the objection. 8. Claims 2-9 and 15-16 are objected to as being dependent on rejected claim 1. 9. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REI TSANG SHIAO whose telephone number is (571)272-0707. The examiner can normally be reached on 8:30 am-5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REI TSANG SHIAO/ Rei-tsang Shiao, Ph.D.Primary Examiner, Art Unit 1691 June 15, 2026
Read full office action

Prosecution Timeline

Dec 11, 2023
Application Filed
Feb 09, 2026
Non-Final Rejection mailed — §DP
May 11, 2026
Response Filed
Jun 18, 2026
Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678434
COMPOSITIONS AND METHODS FOR MODULATING ACE2 RECEPTOR
3y 9m to grant Granted Jul 14, 2026
Patent 12678430
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS
3y 7m to grant Granted Jul 14, 2026
Patent 12678421
COMPOSITION FOR ENHANCING NAMPT GENE EXPRESSION
3y 4m to grant Granted Jul 14, 2026
Patent 12673915
PRECURSOR COMPOUND OF HEXAHYDRO-BETA-ACID COMPONENT COMPOUND, FEED COMPOSITION AND USE THEREOF
3y 1m to grant Granted Jul 07, 2026
Patent 12661348
SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR TG2-RELATED DISEASES
3y 8m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
80%
Grant Probability
46%
With Interview (-34.0%)
2y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 2053 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month